Reticulon 4 isoform Nogo-A (Nogo-A) (Nogo-A)

Reticulon 4 isoform Nogo-A, commonly known as Nogo-A, is a high-molecular-weight transmembrane protein primarily expressed by oligodendrocytes and specific neuronal populations in the central nervous system (CNS) [1.1.1, 1.2.3]. As the largest isoform of the RTN4 gene, it serves as a potent inhibitor of neurite outgrowth and axonal regeneration, playing a critical role in maintaining the structural stability of the adult CNS [1.1.3, 1.2.4]. Nogo-A exerts its inhibitory effects through two distinct domains—amino-Nogo and Nogo-66—which interact with receptors like NgR1 and S1PR2 to activate the RhoA/ROCK signaling pathway, leading to growth cone collapse [1.1.2, 1.2.5]. In pathological conditions such as spinal cord injury, stroke, and amyotrophic lateral sclerosis (ALS), Nogo-A is a major contributor to the non-permissive environment that prevents functional recovery [1.2.1, 1.3.3]. Therapeutic interventions, including monoclonal antibodies like Ozanezumab and decoy receptors like AXER-204, aim to neutralize Nogo-A to promote axonal sprouting and plasticity [1.3.1, 1.3.2]. Despite its potential as a target for neuroregeneration, challenges remain regarding the timing of treatment and the risk of aberrant neural connections [1.1.1, 1.3.2].

Other names

RTN4RTN4-ANogoNeurite outgrowth inhibitorNI-220/250NSPASYReticulon-4

Neutralization of Nogo-A or blockade of its interaction with the Nogo-66 receptor (NgR1) complex to prevent RhoA/ROCK pathway activation and promote axonal regeneration.